Suppr超能文献

基于薏苡仁成分的双靶向微乳剂用于增强肝肿瘤递送及协同治疗。

Bitargeted microemulsions based on coix seed ingredients for enhanced hepatic tumor delivery and synergistic therapy.

作者信息

Qu Ding, Sun Wenjie, Liu Mingjian, Liu Yuping, Zhou Jing, Chen Yan

机构信息

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China.

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.

出版信息

Int J Pharm. 2016 Apr 30;503(1-2):90-101. doi: 10.1016/j.ijpharm.2016.03.001. Epub 2016 Mar 4.

Abstract

A hepatic tumor bitargeted microemulsions drug delivery system using coix seed oil and coix seed polysaccharide (CP) acting as anticancer components, as well as functional excipients, was developed for enhanced tumor-specific accumulation by CP-mediated enhancement on passive tumor targeting and modification of galactose stearate (tumor-targeted ligand). In the physicochemical characteristics studies, galactose stearate-modified coix seed multicomponent microemulsions containing 30% CP (w%) (Gal-C-MEs) had a well-defined spherical shape with a small size (47.63 ± 1.41 nm), a narrow polydispersity index (PDI, 0.101 ± 0.002), and a nearly neutral surface charge (-4.37 ± 1.76 mV). The half-maximal inhibitory concentration (IC50) of Gal-C-MEs against HepG2 cells was 70.2 μg/mL, which decreased by 1.8-fold in comparison with that of coix seed multicomponent microemulsions (C-MEs). The fluorescence intensity of fluorescein isothiocyanate (FITC)-loaded Gal-C-MEs (FITC-Gal-C-MEs) internalized by HepG2 cells was 1.8-fold higher than that of FITC-loaded C-MEs (FIT C-C-MEs), but the cellular uptake of the latter became reduce by 1.6-fold when the weight ratio of CP decreased up to 10%. In the cell apoptosis studies, C-MEs (containing 30% CP) did not show a significant difference with Gal-C-MEs, but exhibited 3.3-fold and 1.5-fold increase relative to C-MEs containing 10% CP and 20% CP, respectively. In the in vivo tumor targeting studies, Cy5-loaded Gal-C-MEs (Cy5-Gal-C-MEs), notably distributed in the tumor sites and still found even at 48 h post-administration, displayed the strongest capability of tumor tissue accumulation and retention among all the test groups. Most importantly, Gal-C-MEs had stronger inhibition of tumor growth, prolonged survival time and more effectively tumor cell apoptosis induction in comparison with C-MEs containing different amounts of CP, which further confirmed that a certain amount of CP and tumor-targeted ligand were of great importance to potent anticancer efficacy. The aforementioned results suggested that Gal-C-MEs presented promising potential as a highly effective and safe anticancer drug delivery system for enhanced liver cancer delivery.

摘要

开发了一种肝肿瘤双靶向微乳给药系统,该系统使用薏苡仁油和薏苡仁多糖(CP)作为抗癌成分以及功能性辅料,通过CP介导增强被动肿瘤靶向作用和修饰硬脂酸半乳糖(肿瘤靶向配体)来增强肿瘤特异性蓄积。在物理化学特性研究中,含有30% CP(w%)的硬脂酸半乳糖修饰的薏苡仁多组分微乳(Gal-C-MEs)具有明确的球形形状,粒径小(47.63±1.41 nm),多分散指数窄(PDI,0.101±0.002),表面电荷接近中性(-4.37±1.76 mV)。Gal-C-MEs对HepG2细胞的半数抑制浓度(IC50)为70.2 μg/mL,与薏苡仁多组分微乳(C-MEs)相比降低了1.8倍。异硫氰酸荧光素(FITC)标记的Gal-C-MEs(FITC-Gal-C-MEs)被HepG2细胞内化后的荧光强度比FITC标记的C-MEs(FITC-C-MEs)高1.8倍,但当CP重量比降至10%时,后者的细胞摄取量降低了1.6倍。在细胞凋亡研究中,C-MEs(含30% CP)与Gal-C-MEs相比无显著差异,但相对于含10% CP和20% CP的C-MEs,分别增加了3.3倍和1.5倍。在体内肿瘤靶向研究中,Cy5标记的Gal-C-MEs(Cy5-Gal-C-MEs)显著分布于肿瘤部位,甚至在给药后48小时仍可检测到,在所有测试组中显示出最强的肿瘤组织蓄积和滞留能力。最重要的是,与含不同量CP的C-MEs相比,Gal-C-MEs对肿瘤生长的抑制作用更强,延长了生存时间,并更有效地诱导肿瘤细胞凋亡,这进一步证实了一定量CP和肿瘤靶向配体对有效抗癌疗效至关重要。上述结果表明,Gal-C-MEs作为一种高效、安全的抗癌药物递送系统,在增强肝癌递送方面具有广阔的应用前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验